A case report showed, after administrated with afatinib as a single agent for 1 month, an EGFR-amplified metastatic CESC patient achieved a partial response (PR), with a significant lesion shrinkage observed (54). The gene discussed is EGFR; the disease is cervical squamous cell carcinoma.